EP1802314A4 - COMPOSITION WITH URIDINE AND METHOD OF APPLICATION THEREFOR - Google Patents

COMPOSITION WITH URIDINE AND METHOD OF APPLICATION THEREFOR

Info

Publication number
EP1802314A4
EP1802314A4 EP05796529A EP05796529A EP1802314A4 EP 1802314 A4 EP1802314 A4 EP 1802314A4 EP 05796529 A EP05796529 A EP 05796529A EP 05796529 A EP05796529 A EP 05796529A EP 1802314 A4 EP1802314 A4 EP 1802314A4
Authority
EP
European Patent Office
Prior art keywords
compositions containing
methods utilizing
utilizing same
containing uridine
uridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP05796529A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1802314A2 (en
Inventor
Richard J Wurtman
Carol Watkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/941,025 external-priority patent/US20050203053A1/en
Priority claimed from US10/944,269 external-priority patent/US8143234B2/en
Priority claimed from US10/972,777 external-priority patent/US8314064B2/en
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of EP1802314A2 publication Critical patent/EP1802314A2/en
Publication of EP1802314A4 publication Critical patent/EP1802314A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
EP05796529A 2004-09-15 2005-09-13 COMPOSITION WITH URIDINE AND METHOD OF APPLICATION THEREFOR Ceased EP1802314A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/941,025 US20050203053A1 (en) 1999-07-30 2004-09-15 Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function
US10/944,269 US8143234B2 (en) 1998-07-31 2004-09-20 Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
US10/972,777 US8314064B2 (en) 1998-07-31 2004-10-26 Uridine administration stimulates membrane production
PCT/US2005/032312 WO2006031683A2 (en) 2004-09-15 2005-09-13 Compositions containing uridine, and methods utilizing same

Publications (2)

Publication Number Publication Date
EP1802314A2 EP1802314A2 (en) 2007-07-04
EP1802314A4 true EP1802314A4 (en) 2011-02-23

Family

ID=36060581

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05796529A Ceased EP1802314A4 (en) 2004-09-15 2005-09-13 COMPOSITION WITH URIDINE AND METHOD OF APPLICATION THEREFOR

Country Status (6)

Country Link
EP (1) EP1802314A4 (ja)
JP (2) JP2008513453A (ja)
CN (1) CN102600199A (ja)
AU (1) AU2005285090A1 (ja)
CA (1) CA2579851C (ja)
WO (1) WO2006031683A2 (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8143234B2 (en) 1998-07-31 2012-03-27 Massachusetts Institute Of Technology Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
US8518882B2 (en) 1998-07-31 2013-08-27 Massachusetts Institute Of Technology Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
US8314064B2 (en) 1998-07-31 2012-11-20 Massachusetts Institute Of Technology Uridine administration stimulates membrane production
CN102600199A (zh) * 2004-09-15 2012-07-25 麻省理工学院 含有尿苷的组合物及使用其的方法
WO2009002148A1 (en) 2007-06-27 2008-12-31 N.V. Nutricia Food composition for prodromal dementia patients
PT2170316E (pt) * 2007-06-26 2014-01-30 Nutricia Nv Melhoramento de memória em indivíduos com exame de estado mini mental de 24-26
WO2009002145A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Lipid composition for improving function of brain functioning
WO2009002146A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Supporting activities of daily living
WO2009057994A1 (en) 2007-11-02 2009-05-07 N.V. Nutricia Unit dosage for brain health
MX2010006829A (es) 2007-12-20 2010-09-30 Nutricia Nv Producto que contiene nucleotidos/nucleosidos liquidos.
WO2012125020A1 (en) * 2011-03-14 2012-09-20 N.V. Nutricia Method for treating neurotrauma
WO2014160502A1 (en) * 2013-03-13 2014-10-02 Tufts University Uridine nucleoside derivatives, compositions and methods of use
CN106822393A (zh) * 2017-02-17 2017-06-13 福建康是美生物科技有限公司 一种增强记忆力的保健胶囊
AU2019215105A1 (en) * 2018-02-01 2020-08-13 Pharma Cinq, Llc Compositions and devices for systemic delivery of uridine
CN115120607A (zh) * 2022-06-07 2022-09-30 珍奥集团股份有限公司 核苷酸混合物在用于防治阿尔茨海默症制剂中的应用
WO2024058276A1 (ja) * 2022-09-16 2024-03-21 ヤマサ醤油株式会社 健常者の総合記憶力を改善する剤及び方法
CN115737666B (zh) * 2022-11-24 2024-03-26 暨南大学 尿苷二磷酸葡萄糖在制备延缓衰老产品中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997045127A1 (en) * 1996-05-28 1997-12-04 Polifarma S.P.A. Uridine-comprising therapeutic active agent for treatment of neurodegenerative disorders
WO2000006174A1 (en) * 1998-07-31 2000-02-10 Massachusetts Institute Of Technology Methods for increasing cytidine levels in vivo and treating cytidine-dependent human diseases
US20030114415A1 (en) * 2001-12-14 2003-06-19 Wurtman Richard J. Compositions and methods for treating and preventing memory impairment using citicoline
WO2005079250A2 (en) * 2004-02-13 2005-09-01 Cornell Research Foundation, Inc. Purines are self-renewal signals for neural stem cells, and purine receptor antagonists promote neuronal and glial differentiation therefrom
WO2005112635A2 (en) * 2004-05-13 2005-12-01 Massachusetts Institute Of Technology Uridine effects on dopamine release

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3011A (en) * 1843-03-21 Improvement in water-wheels
BR9709379A (pt) * 1996-05-28 2000-01-11 Polifarma Spa Uso de uridina, e, composição para o tratamento de distúrbios do sistema nervoso devido à degeneração seletiva de células neuroniais ou gliais em mamìferos.
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
JP2001233776A (ja) * 2000-02-25 2001-08-28 Yamasa Shoyu Co Ltd 学習・記憶能低下改善剤およびその用途
CN102600199A (zh) * 2004-09-15 2012-07-25 麻省理工学院 含有尿苷的组合物及使用其的方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997045127A1 (en) * 1996-05-28 1997-12-04 Polifarma S.P.A. Uridine-comprising therapeutic active agent for treatment of neurodegenerative disorders
WO2000006174A1 (en) * 1998-07-31 2000-02-10 Massachusetts Institute Of Technology Methods for increasing cytidine levels in vivo and treating cytidine-dependent human diseases
US20030114415A1 (en) * 2001-12-14 2003-06-19 Wurtman Richard J. Compositions and methods for treating and preventing memory impairment using citicoline
WO2005079250A2 (en) * 2004-02-13 2005-09-01 Cornell Research Foundation, Inc. Purines are self-renewal signals for neural stem cells, and purine receptor antagonists promote neuronal and glial differentiation therefrom
WO2005112635A2 (en) * 2004-05-13 2005-12-01 Massachusetts Institute Of Technology Uridine effects on dopamine release

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CACABELOS R ET AL: "THERAPEUTIC EFFECTS OF CDP-CHOLINE IN ALZHEIMER'S DISEASE COGNITION, BRAIN MAPPING, CEREBROVASCULAR HEMODYNAMICS, AND IMMUNE FACTORS", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, NEW YORK ACADEMY OF SCIENCES, NEW YORK, NY, US, 1 January 1996 (1996-01-01), pages 399 - 403, XP008065562, ISSN: 0077-8923, DOI: 10.1111/J.1749-6632.1996.TB34452.X *
DE BRUIN N M W J ET AL: "Combined uridine and choline administration improves cognitive deficits in spontaneously hypertensive rats", NEUROBIOLOGY OF LEARNING AND MEMORY, SAN DIEGO, US, vol. 80, no. 1, 1 July 2003 (2003-07-01), pages 63 - 79, XP002603409, ISSN: 1074-7427, [retrieved on 20030411], DOI: 10.1016/S1074-7427(03)00024-8 *
SPIERS P A ET AL: "CITICOLINE IMPROVES VERBAL MEMORY IN AGING", ARCHIVES OF NEUROLOGY, AMERICAN MEDICAL ASSOCIATION, CHICAGO, IL, US, vol. 53, no. 5, 1 May 1996 (1996-05-01), pages 441 - 448, XP008028412, ISSN: 0003-9942 *

Also Published As

Publication number Publication date
AU2005285090A1 (en) 2006-03-23
CN102600199A (zh) 2012-07-25
JP2013064026A (ja) 2013-04-11
JP2008513453A (ja) 2008-05-01
WO2006031683A3 (en) 2006-12-21
CA2579851C (en) 2018-09-04
JP6141643B2 (ja) 2017-06-07
EP1802314A2 (en) 2007-07-04
CA2579851A1 (en) 2006-03-23
WO2006031683A2 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
IL181810A0 (en) Compositions containing uridine, and methods utilizing same
EP1802314A4 (en) COMPOSITION WITH URIDINE AND METHOD OF APPLICATION THEREFOR
HK1209729A1 (en) Compounds, compositions and methods
IL178860A0 (en) Certain chemical entities, compositions, and methods
EP1646382A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
EP1692112A4 (en) COMPOUNDS, COMPOSITIONS, AND METHODS
AP2280A (en) Compositions and methods for increasing telomeraseactivity.
IL209494A (en) Formulations of insulin oligomeric monoconogues and their use
EP1799700A4 (en) SRAGE MIMETIC BODIES, COMPOSITIONS, PROCESSES AND USES
EP1664746A4 (en) ANTIOXIDANT SENSOR, METHODS AND COMPOSITIONS THEREFOR
IL182765A0 (en) Pyridazine compounds, compositions and methods
IL175300A0 (en) Indirubin-type compounds, compositions, and methods for their use
EP1962852A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
EP1959960A4 (en) Specific chemical properties, compositions and methods
EP1838800A4 (en) COMPOSITIONS, REDOX COUPLES AND THEIR USE
IL184062A0 (en) Visco-supplement composition and methods
EP1711527A4 (en) HLA-DR SPECIFIC ANTIBODIES, COMPOSITIONS AND METHODS
EP1675834A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
EP1594849A4 (en) COMPOUNDS, COMPOSITIONS, AND METHODS
EP1680420A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
GB0307695D0 (en) Compounds,compositions and processes
EP1620092A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
IL177759A0 (en) Cospeptin, cosmedin and their uses
EP1706111A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
GB0417036D0 (en) Compounds, compositions and devices

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070416

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MASSACHUSETTS INSTITUTE OF TECHNOLOGY

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20110120

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MASSACHUSETTS INSTITUTE OF TECHNOLOGY

17Q First examination report despatched

Effective date: 20130510

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20210716